| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 8 | 2025 | 167 | 2.620 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2021 | 68 | 1.550 |
Why?
|
| Immunization, Passive | 9 | 2024 | 99 | 1.040 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2025 | 75 | 0.920 |
Why?
|
| Antibodies, Bispecific | 2 | 2023 | 29 | 0.920 |
Why?
|
| Neoplastic Stem Cells | 4 | 2013 | 196 | 0.880 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.880 |
Why?
|
| Urticaria | 1 | 2023 | 7 | 0.860 |
Why?
|
| Mutation | 5 | 2025 | 2455 | 0.840 |
Why?
|
| Transfusion Reaction | 1 | 2023 | 44 | 0.840 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 23 | 0.720 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 45 | 0.710 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 75 | 0.690 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 328 | 0.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 402 | 0.620 |
Why?
|
| Vaccination | 1 | 2021 | 335 | 0.610 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1151 | 0.570 |
Why?
|
| Leukemia | 2 | 2016 | 57 | 0.530 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2016 | 11 | 0.510 |
Why?
|
| Antigens, CD34 | 3 | 2017 | 54 | 0.510 |
Why?
|
| Humans | 43 | 2025 | 59391 | 0.510 |
Why?
|
| Neoplasms | 3 | 2023 | 1231 | 0.480 |
Why?
|
| Phenotype | 2 | 2016 | 1137 | 0.470 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 628 | 0.470 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 62 | 0.450 |
Why?
|
| Stem Cells | 2 | 2013 | 255 | 0.440 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2013 | 276 | 0.440 |
Why?
|
| Transplantation Conditioning | 2 | 2024 | 98 | 0.380 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 397 | 0.360 |
Why?
|
| Disease Progression | 4 | 2024 | 1119 | 0.350 |
Why?
|
| Biomarkers | 1 | 2016 | 1306 | 0.350 |
Why?
|
| Outpatients | 4 | 2024 | 137 | 0.340 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2020 | 18 | 0.310 |
Why?
|
| Adult | 14 | 2025 | 15685 | 0.300 |
Why?
|
| Cytarabine | 2 | 2020 | 32 | 0.300 |
Why?
|
| Aged | 12 | 2025 | 13407 | 0.290 |
Why?
|
| Middle Aged | 12 | 2025 | 16312 | 0.270 |
Why?
|
| Male | 17 | 2025 | 27749 | 0.270 |
Why?
|
| Female | 18 | 2025 | 30731 | 0.270 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 292 | 0.240 |
Why?
|
| Prognosis | 4 | 2025 | 1597 | 0.230 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.220 |
Why?
|
| Staurosporine | 1 | 2024 | 19 | 0.220 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.220 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 105 | 0.210 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 168 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 170 | 0.200 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 384 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 318 | 0.200 |
Why?
|
| Repressor Proteins | 1 | 2024 | 331 | 0.190 |
Why?
|
| Blast Crisis | 1 | 2021 | 10 | 0.190 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2012 | 29 | 0.190 |
Why?
|
| Genes, p53 | 1 | 2021 | 52 | 0.190 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5119 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 92 | 0.180 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 181 | 0.170 |
Why?
|
| Tretinoin | 3 | 2017 | 49 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 931 | 0.170 |
Why?
|
| Anthracyclines | 1 | 2020 | 10 | 0.170 |
Why?
|
| Mice, SCID | 2 | 2012 | 513 | 0.170 |
Why?
|
| Allografts | 1 | 2020 | 44 | 0.170 |
Why?
|
| Mice, Inbred NOD | 2 | 2012 | 516 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2019 | 7 | 0.170 |
Why?
|
| Voriconazole | 1 | 2019 | 6 | 0.170 |
Why?
|
| Invasive Fungal Infections | 1 | 2019 | 7 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 678 | 0.160 |
Why?
|
| Hospitalization | 2 | 2024 | 1292 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 289 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 85 | 0.160 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 10 | 0.160 |
Why?
|
| Antifungal Agents | 1 | 2019 | 120 | 0.160 |
Why?
|
| Immunophenotyping | 2 | 2016 | 184 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2018 | 62 | 0.150 |
Why?
|
| Bone Marrow | 3 | 2016 | 177 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 217 | 0.150 |
Why?
|
| United States | 5 | 2023 | 7431 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 308 | 0.150 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 44 | 0.150 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 185 | 0.150 |
Why?
|
| Myelopoiesis | 1 | 2017 | 14 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2024 | 715 | 0.140 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.130 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2016 | 4 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2017 | 2899 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 365 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 43 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2016 | 2 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 2016 | 4 | 0.130 |
Why?
|
| Mastocytosis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2016 | 5 | 0.130 |
Why?
|
| Etoposide | 1 | 2016 | 33 | 0.130 |
Why?
|
| Karyotyping | 1 | 2016 | 44 | 0.130 |
Why?
|
| Dermatomycoses | 1 | 2016 | 13 | 0.130 |
Why?
|
| Leukopenia | 1 | 2016 | 16 | 0.130 |
Why?
|
| Niacinamide | 1 | 2016 | 32 | 0.130 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 30 | 0.130 |
Why?
|
| Cell Differentiation | 4 | 2017 | 1304 | 0.130 |
Why?
|
| Lymph Nodes | 2 | 2013 | 215 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2017 | 186 | 0.120 |
Why?
|
| Young Adult | 4 | 2025 | 4272 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2016 | 172 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 152 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 325 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1480 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 234 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2013 | 941 | 0.120 |
Why?
|
| Down-Regulation | 2 | 2013 | 306 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 396 | 0.120 |
Why?
|
| Neutrophils | 1 | 2017 | 365 | 0.110 |
Why?
|
| Mice | 6 | 2013 | 10291 | 0.110 |
Why?
|
| Automation, Laboratory | 1 | 2013 | 8 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2024 | 143 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 34 | 0.110 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 16 | 0.110 |
Why?
|
| Splenic Rupture | 1 | 2013 | 2 | 0.110 |
Why?
|
| Sarcoma, Myeloid | 1 | 2013 | 3 | 0.110 |
Why?
|
| Cyclin D1 | 1 | 2013 | 19 | 0.110 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2013 | 14 | 0.110 |
Why?
|
| Recurrence | 2 | 2012 | 602 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 63 | 0.100 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 54 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 450 | 0.100 |
Why?
|
| Transplantation, Autologous | 2 | 2024 | 119 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2024 | 5283 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 170 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2013 | 365 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 38 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2092 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 138 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 145 | 0.090 |
Why?
|
| Cytosine | 1 | 2011 | 31 | 0.090 |
Why?
|
| DNA Repair | 1 | 2013 | 242 | 0.090 |
Why?
|
| WT1 Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 45 | 0.090 |
Why?
|
| Myeloblastin | 1 | 2011 | 14 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 13 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 38 | 0.090 |
Why?
|
| Telomerase | 1 | 2011 | 31 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 161 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 110 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 133 | 0.080 |
Why?
|
| Transcriptome | 1 | 2013 | 340 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2023 | 3066 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 718 | 0.080 |
Why?
|
| Cytokines | 2 | 2023 | 912 | 0.080 |
Why?
|
| Animals | 6 | 2013 | 19649 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 215 | 0.080 |
Why?
|
| Adolescent | 3 | 2024 | 5838 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 323 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 55 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 836 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1206 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 339 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 617 | 0.070 |
Why?
|
| Cell Movement | 1 | 2009 | 428 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 550 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1466 | 0.060 |
Why?
|
| Transplantation, Haploidentical | 1 | 2024 | 3 | 0.060 |
Why?
|
| HLA Antigens | 1 | 2024 | 61 | 0.060 |
Why?
|
| Blood Donors | 1 | 2024 | 22 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 244 | 0.060 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2024 | 25 | 0.060 |
Why?
|
| Interleukin-7 | 1 | 2023 | 30 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 263 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2023 | 87 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 6 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2023 | 29 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 170 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 179 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1118 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 178 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 309 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 446 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 197 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 95 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2024 | 6071 | 0.040 |
Why?
|
| Sweden | 1 | 2020 | 42 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 144 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2022 | 304 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 54 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2020 | 260 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 61 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 805 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 617 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2017 | 25 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2017 | 26 | 0.030 |
Why?
|
| Neutrophil Activation | 1 | 2017 | 24 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1099 | 0.030 |
Why?
|
| Lactoferrin | 1 | 2017 | 36 | 0.030 |
Why?
|
| Isoleucine | 1 | 2016 | 9 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 53 | 0.030 |
Why?
|
| Exocytosis | 1 | 2017 | 59 | 0.030 |
Why?
|
| Threonine | 1 | 2016 | 15 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 59 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 129 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 225 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 5 | 0.030 |
Why?
|
| Arsenicals | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2218 | 0.030 |
Why?
|
| Oxides | 1 | 2016 | 33 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 1507 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 234 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 645 | 0.030 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2013 | 3 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2013 | 4 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 25 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 26 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 79 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 60 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 22 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 106 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2013 | 55 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2013 | 136 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 31 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 289 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 191 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1555 | 0.020 |
Why?
|
| Spleen | 1 | 2013 | 479 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 410 | 0.020 |
Why?
|
| 5-Methylcytosine | 1 | 2011 | 20 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 178 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 179 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 156 | 0.020 |
Why?
|
| Software | 1 | 2013 | 366 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 608 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 847 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 587 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1557 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2009 | 76 | 0.020 |
Why?
|
| Child | 1 | 2016 | 4190 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 1368 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3231 | 0.010 |
Why?
|